I
nflammatory bowel disease (IBD) and foreign travel are associated with an increased risk of travel-related morbidity brought on by exacerbations of IBD, acquisition of infectious diseases endemic to the destination, and availability of health care and medicines while abroad (Ben-Horin et al, 2012; Rahier et al, 2014) . Patients receiving immunosuppressive medication have an increased susceptibility to these infections as well as an attenuated immune response to vaccinations (Rahier et al, 2010; 2014; Wasan et al, 2010) . Detailed pre-travel consultations and vaccinations are advised prior to travel to ensure travellers are armed with the appropriate education and resources to stay healthy during their journey (Rahier et al, 2014) . Despite guidelines (Rahier et al, 2014) specifying appropriate vaccination strategies for IBD patients, knowledge and provision of this information have been found to be poor, particularly vaccination for those on immunosuppressive medication (Gupta et al, 2011; Wasan et al, 2011; Yeung et al, 2011 ).
Low counselling rates for avoidance of live vaccines and inadequate understanding and knowledge of vaccinations have been cited in previous research (Yeung et al, 2011; Wasan et al, 2011; 2014) . Possible explanations for this include health professionals' lack of awareness; ambiguity regarding who should assume responsibility for vaccine administration; and concerns regarding safety and efficacy of vaccinations, including fear of vaccine-induced exacerbations of IBD (Yeung et al, 2011; Wasan et al, 2011; 2014) . The European Crohn's and Colitis Organisation (ECCO) guidelines (Rahier et al, 2014) recommend that travel consultations should be provided jointly by a gastroenterologist and expert travel clinic. Deficiencies in the advice provided by such clinics have been highlighted in previous research (Soonawala et al, 2012) , which found that 27% of patients were incorrectly given the yellow fever vaccination while receiving immunomodulator therapy. This highlights the need for travel clinics to have increased
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Developing an evidence-based online travel resource for inflammatory bowel disease technology © 2014 MA Healthcare Ltd vigilance when prescribing live vaccinations, and suggests further research is needed to investigate the content and accuracy of information given by health professionals and how appropriately they address the issues relevant to IBD patients.
The aim of this study was to explore the IBD patient's experience of travel, including pre-travel preparation, and to examine the availability of travel information, in order to evaluate and improve the quality and provision of pre-travel advice.
Literature review
Existing research and resources regarding IBD and travel were identified using OvidSP and major internet search engines ( Table 1) . The search terms used were 'inflammatory bowel disease', 'Crohn's disease', 'ulcerative colitis', 'vaccination', 'travel', and 'travel health'. The ECCO consensus statement on managing opportunistic infections in IBD (Rahier et al, 2014) provides comprehensive information on experiencing travellers' diarrhoea, managing the symptomatic returning traveller, and advising patients travelling to developing countries, but it does not provide details for travel to developed countries and travel health specialists may not be familiar with the guidelines.
There is limited research looking specifically into travel-associated health risks and health preparation in patients with IBD. Only two empirical studies were found that focused specifically on travel and IBD. Soonawala et al (2012) examined pre-travel preparation and travel-related morbidity in a retrospective survey of 277 Dutch patients with IBD. The authors categorised travel according to destinations 
Facilities of destination
Local IBD centres at destination technology where hepatitis A is endemic and requiring vaccination, according to their national guideline. The study found that IBD limited travel in the majority of patients and this was greater for patients on anti-TNF medication. The authors found that one in four patients travelling to less developed countries failed to obtain pre-travel advice and vaccinations and that there was significant travel-related morbidity experienced by IBD patients, although they did not have a control group to compare with.
The incidence and rate of travel-associated health risks in IBD patients was investigated by Ben-Horin et al (2012) , who conducted a retrospective, case-controlled study using structured questionnaires, interviews, and case-note review. Travel destination was classified according to economic development, and rates of illness were compared between travel to developed and developing countries. The immune-status of the traveller was also analysed against the risk of travel-associated diseases. The results of the study suggest that IBD patients avoid travelling to less developed counties compared with healthy controls. The majority of illness abroad in both groups was related to self-limiting abdominal symptoms. The main risk factor for illness while abroad was severity of IBD. No difference was found in the risk of illness in IBD patients on immunosuppression compared with healthy controls.
The internet search found a paucity of information for IBD patients wishing to travel and the quality of online material was found to be inconsistent. Generic travel health and UK Government websites provide information regarding risk assessment and management of vaccine-preventable diseases, but this can be confusing to navigate and interpret in relation to IBD-specific risk factors, such as patients on immunomodulator therapy. Patient organisation websites in both the UK and worldwide offer varied but reputable information that is limited to general IBD-related travel advice but whose remit does not cover information provided in national and international IBD guidelines. No single resource is available to provide transparent, comprehensive, evidencebased information to adequately inform both patients and health professionals on IBD-specific travel issues.
Method
The author conducted a review of 150 IBD patients attending a London teaching hospital outpatient clinic from October to December 2013.
Survey design
A structured, anonymous questionnaire was developed and piloted on a sample of 10 patients attending the IBD clinic using a 32-item paper questionnaire. Minor changes were made to some questions to produce the final version of the questionnaire. The selfadministered survey contained 32 questions on demographics and disease characteristics. Also included were detailed travel questions regarding last travel overseas, as well as experience of travelling with IBD; pre-travel preparation undertaken; and knowledge of travelrelated health issues, such as vaccinations and insurance. 
Statistical analysis
Data were entered and analysed using Microsoft Excel. Descriptive statistics were used to characterise the population and data.
Data analysis and results
A total of 136 IBD patients completed the questionnaire (Crohn's disease (CD): 67/136, 49%; male 60/136, 44%; 91% response rate). The respondents' median age was 38 years (range 18-85 years). At the time of the survey, 69/136 (51%) were using a combination of single or dual immunomodulator therapy; of these 69, 30% were on corticosteroids, 81% on thiopurine, 45% on anti-TNF therapy, and 7% on methotrexate. Among all the respondents, 36% (49/136) had previously had IBD-related surgery. The demographic characteristics are shown in Table 2 .
All participants were asked whether having IBD influenced their decision to travel abroad or their choice of destination. A total of 97% (132/136) of the respondents had travelled overseas in the past 5 years. Of these, the majority reported that IBD affected their travel (62%, 82/132), and 61% (80/132) stated that IBD limited their choice of travel destination. Europe was the main destination for 52% of travellers, with 23% (30/132) visiting developing countries. With regard to alteration in bowel habit, 28/132 (21%) of the respondents stated that they experienced it and thought it was related to their IBD; of these 28, only 2 had a confirmed infective cause for their symptoms, while 14 were not tested. Table 3 lists the travel characteristics of the respondents. Only 23% (31/132) of the travellers sought pre-travel medical advice of any kind (Figures 1 and 2) . Travel insurance that covered IBD was obtained by only 40% (53/132) of all patients, the majority of whom (70%; 37/53) paid an increased premium; the survey did not ascertain whether this was because of their IBD or another cause. The survey results also found that 52% (36/69) of respondents on immunomodulator therapy were unaware of the need to avoid live vaccines. Differences in the type of medication patients were taking and the pre-travel preparation sought was also examined ( Table 4) . There was no difference between patients taking immunosuppression and those on mesalazine alone with regard to advice sought prior to travel and perceived limitations of travel with IBD. Three times the percentage of patients on immunosuppressant therapy compared with those on mesalazine sought vaccination advice (15% (10/69) vs 5% (2/39)) and obtained travel insurance (40% (28/69) vs 8% (3/39)).
Discussion
A minority of patients (23%) in this study undertook pre-travel preparation. Although vaccination, insurance, and general advice were the main areas of interest for those who sought information, low numbers of patients in this group actually went on to obtain travel insurance to cover their IBD-implying that most were possibly under-or not insured. This trend could be attributed to: inadequacies in the information given at the time of consultation; lack of knowledge regarding how to source adequate information, such as travel insurance; and external factors including increased premiums for those with pre-existing medical conditions, particularly when recovering from a period of illness. Previous research found that IBD patients travelling to developing countries are no more at risk of developing enteric infections compared with healthy counterparts, although many individuals with IBD would avoid these destinations for this reason (Ben-Horin et al, 2012) . We found similar results, with most individuals citing concerns over toilet facilities, sanitation, and a greater risk of contracting enteric infections as the main reasons for avoiding particular destinations.
Travel overseas is becoming more prevalent and forms part of maintaining a balanced quality of life (UNWTO World Tourism Organization, 2014). The overall effect of IBD and the restrictions imposed on daily life have been documented in a recent European survey (Wilson et al, 2012) and it indicates that most individuals faced disruptions in their daily life caused by the status of their disease, but over half avoided cancelling or rescheduling plans. The availability of toilets remains one of the main concerns of individuals with IBD (Wilson et al, 2012) .
The findings from this study showed that more than half the number of patients receiving immunomodulator therapy were unaware that they should avoid live vaccines. Differences were also seen in those who were taking immunosuppressant medication, with this patient group more likely to obtain travel insurance and vaccination advice compared with those on mesalazine alone. This would suggest that patients who have a more complicated disease course are more likely to seek pre-travel advice.
Limitations
There are several limitations in this study. First, the retrospective survey design required respondents to recall their last overseas trip, which may introduce recall bias regarding specific details of 
Development of IBDPassport
The results of the literature and internet searches revealed a paucity of information for IBD patients wishing to travel. Generic travel-health websites provide information regarding risk assessment and management of vaccine-preventable diseases, but this can be confusing to navigate and interpret in relation to IBD-specific risk factors, such as patients on immunomodulator therapy. No single resource was found that could provide transparent, comprehensive, evidencebased information to adequately inform both IBD patients and health professionals on IBD-specific travel issues. Using data collected from the patient survey and extensive literature searches, the author identified a gap in literature and developed IBDPassportwww.ibdpassport.com-an online travel resource for IBD. The website was developed for both IBD patients and health professionals as a non-profit, IBD-specific travel resource with the primary aim of developing patient-centred information to support living with IBD and improve education and pre-travel preparation by providing evidencebased information on all aspects of travel and IBD.
The website draws together evidence-based information from national and international IBD guidelines, patient organisations, and government literature into one resource. The main focus of IBDPassport is the 'Travelling with IBD' and 'IBD Network' pages. Travelling with IBD includes practical information on issues such as obtaining health care overseas, managing travellers' diarrhoea, travel following surgery and details regarding travel insurance and vaccination advice specific to immunocompromised patients.
The IBD Network page contains an interactive map of country-specific vaccination advice and a 'search and refer' directory of IBD centres to enable IBD health professionals to refer to other IBD centres globally. Populating the directory of IBD centres depends on those centres registering with the site, although some IBD centres will be manually entered by the author to ensure the information is comprehensive and useful to users.
From idea to implementation
Following initial research and the identified need for a resource to support IBD patients planning to travel overseas, the author contacted a web development agency to explore the possibility, process and cost of development. A web-based approach was chosen, since research investigating IBD patients' use of the internet for health-related information demonstrated that the internet is a major source of disease -specific information that can support the education process and assist in decision making (Cima et al, 2012; Fortinsky et al, 2012; Greveson et al, 2014) . The internet is widely used and offers a wealth of information for patients with chronic disease (Fox, 2007) ; however, this information can often be unregulated and potentially inaccurate (Van der Marel et al, 2009 ). The aim was to create a resource with accurate, evidence-based content, that was user-friendly and valuable to both patients and health professionals, while avoiding the pitfalls usually encountered with online material, such as poor quality content (Bernard et al, 2007; Langille et al, 2010) .
Initial funding for the project was obtained from a Nurse Innovation Award presented by Shire Pharmaceuticals. The remaining cost The project was undertaken predominantly in the author's own time; therefore, there were difficulties encountered in devoting time to conducting the extensive literature searches necessary to research and write the content to ensure a comprehensive, accurate, evidencebased resource.
Dissemination
The fundamental aim of the IBDPassport project is to improve awareness of issues related to travel and IBD and improve the quality of information available. Dissemination is a key process in implementation. The author has worked closely with Crohn's and Colitis UK, which will be featuring details of the website in a members' newsletter. A link to the IBDPassport website has been circulated in newsletters from the British Society of Gastroenterology (BSG), Primary Care Society of Gastroenterology, and the nurses' arm of ECCO. The author also intends to raise awareness through social media and links with the Royal College of Nursing IBD Nurse Forum. The final stage in implementation will be the formal evaluation by key users, who use recognised health-website quality-evaluation tools to inform further development and improvement.
Conclusion
This paper presents the first comprehensive webbased travel resource developed for both IBD patients and health professionals and providing evidence-based IBD and country-specific travel information. The next step in the development process is to formally evaluate IBDPassport with the help of IBD patients, health professionals, and the patient charity Crohn's and Colitis UK. It is hoped that this evidence-based resource will become a reliable and reputable resource for IBD-related travel information, and that it will help to reduce travel-related morbidity through improved awareness, education, and patient involvement. 
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